Today: 22 July 2026
Browse Category

Pharmaceuticals 12 January 2026 - 14 January 2026

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as a “major amendment” but didn’t request additional safety or manufacturing data. LGND shares opened at $196.96 and fluctuated between $175.89 and $206.78.
13 January 2026
···
Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson stock jumps as Delaware court pares Auris damages hit, earnings next week

Johnson & Johnson shares climbed roughly 1.6% to $212.98 on Tuesday, bucking a minor slide in healthcare stocks as the overall market showed little direction. The stock hit a session peak of $213.48 and dipped to $208.93 at its low. Meanwhile, the Health Care Select Sector SPDR ETF fell around 0.3%, with the S&P 500 ETF holding steady.
13 January 2026
···
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration's request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo Nordisk’s Wegovy.
13 January 2026
···
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer Inc shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029.
13 January 2026
····
Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck & Co boosted its long-term revenue forecast for several new products and pipeline candidates, projecting $70 billion from these “new growth drivers” by the mid-2030s. The company raised its cardiometabolic and respiratory sales outlook to around $20 billion, up from $15 billion, while its infectious-disease forecast jumped to about $15 billion from $5 billion. Merck shares slipped 1.2% to close at $109.19 on Monday. Meanwhile, Johnson & Johnson climbed 2.6%, Eli Lilly added 1.6%, and Pfizer dropped 0.8%.
13 January 2026
··
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer Inc. shares fell on Monday after Chief Executive Albert Bourla said the cash-pay market for obesity drugs — where patients pay out of pocket — now works “almost like Viagra”, the erectile-dysfunction drug Pfizer launched in 1998. The company, which bought obesity developer Metsera in a deal valued at up to $10 billion and has said it does not expect to return to revenue growth until 2029, closed down 0.8% at $25.27.
13 January 2026
···
1 … 18 19 20 21 22 … 44
Go toTop